Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

If you said diabetes, you're right -- a new study finds diabetes costs $101 billion annually in diagnosis and treatment and ...

CEO Lars Fruergaard Jorgensen expressed concern, stating that only Novo Nordisk makes real semaglutide and does not supply it ...

“Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN ...

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Jorgensen resigned from UK in June 2023, receiving $75,000 as he departed. At the time, he was the focus of misconduct ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and ...

“Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access to a safe ...

Novo Nordisk President and CEO Lars Fruergaard Jorgensen, shown testifying on Capitol Hill in September, is warning about potential risks from compounded versions of the drug semaglutide.